C4 Therapeutics (NASDAQ:CCCC - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $4.33 million for the quarter.
C4 Therapeutics Trading Down 0.6 %
Shares of NASDAQ:CCCC traded down $0.02 on Friday, reaching $3.18. The company had a trading volume of 1,812,688 shares, compared to its average volume of 1,845,150. C4 Therapeutics has a 52-week low of $3.15 and a 52-week high of $11.88. The firm's 50 day simple moving average is $3.78 and its 200-day simple moving average is $5.00. The firm has a market capitalization of $224.48 million, a PE ratio of -1.87 and a beta of 2.95.
Wall Street Analysts Forecast Growth
CCCC has been the topic of a number of analyst reports. Stephens initiated coverage on C4 Therapeutics in a report on Monday, November 18th. They issued an "equal weight" rating and a $4.00 price target on the stock. Wells Fargo & Company upgraded C4 Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $8.00 to $12.00 in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, C4 Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $11.60.
Read Our Latest Stock Report on CCCC
About C4 Therapeutics
(
Get Free Report)
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Further Reading
Before you consider C4 Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and C4 Therapeutics wasn't on the list.
While C4 Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
